Persistent PSA could be used as an independent predictor of worse long-term outcomes in the high-risk PCa patients, while in the intermediate-risk patients this parameter significantly predicts only biochemical recurrence and has no impact on outcomes in the low-risk PCa patients. This evidence concerns the gene KLK3 and posterior cortical atrophy.